Search Results

You are looking at 61 - 70 of 1,088 items for :

  • "Lung cancer" x
  • Refine by Access: All x
Clear All
Full access

Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer

Ryan D. Gentzler and Jyoti D. Patel

During the past 10 years, the treatment of advanced-stage non-small cell lung cancer (NSCLC) has become increasingly complex. From the use of newer chemotherapeutics in platinum-based doublets to the introduction of targeted agents and maintenance

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

associated with high FN risk for breast or lung cancer in preparation for future comparative effectiveness studies with G-CSF biosimilars. This work will inform future observational comparative safety and effectiveness analyses of G-CSF biosimilars

Full access

Management of Recurrent Small Cell Lung Cancer

Bryan J. Schneider

supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer . J Clin Oncol 2006 ; 24 : 5441 – 5447 . 2. Postmus PE Berendsen HH van Zandwijk . Retreatment with the induction regimen in small

Full access

NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022

Featured Updates to the NCCN Guidelines

Douglas E. Wood, Ella A. Kazerooni, Denise Aberle, Abigail Berman, Lisa M. Brown, Georgie A. Eapen, David S. Ettinger, J. Scott Ferguson, Lifang Hou, Dipen Kadaria, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Peter Mazzone, Robert E. Merritt, David E. Midthun, Mark Onaitis, Sudhakar Pipavath, Christie Pratt, Varun Puri, Dan Raz, Chakravarthy Reddy, Mary E. Reid, Kim L. Sandler, Jacob Sands, Matthew B. Schabath, Jamie L. Studts, Lynn Tanoue, Betty C. Tong, William D. Travis, Benjamin Wei, Kenneth Westover, Stephen C. Yang, Beth McCullough, and Miranda Hughes

: July 10, 2022; Expiration date: July 10, 2023 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Lung Cancer Screening

Full access

Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non–Small Cell Lung Cancer: Analysis of the SEER Database

Fei Gao, Nan Li, YongMei Xu, and GuoWang Yang

Background Non–small cell lung cancer (NSCLC) accounts for approximately 85% of patients with lung cancer. 1 The features of patients with stage IIIA disease are highly heterogeneous, and surgery is the preferred treatment, but these patients are

Full access

Treating and Preventing Lung Cancer

Rodger J. Winn

. Smoking behavior of 226 patients with diagnosis of stage IIIA/StageB non-small lung cancer . Psychooncology 2002 ; 11 : 472 - 478 . 3 Videtic GMM Stitt SW Dar R . Continued cigarette smoking by patients receiving concurrent chemoradiotherapy

Full access

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N. Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, and Hema Sundar

Disclosures for the Non–Small Cell Lung Cancer Panel References 1. Siegel RL Miller KD Jemal A . Cancer Statistics, 2017 . CA Cancer J Clin 2017 ; 67 : 7 – 30 . 2. Swerdlow SH Campo E Harris NL , eds. WHO Classification of

Full access

In Chemotherapy for Lung Cancer, Sometimes Less is More

Eric Roeland, Charles Loprinzi, Timothy J. Moynihan, Thomas J. Smith, and Jennifer Temel

prolonged survival, and palliate symptoms. Lung cancer remains the leading cause of cancer-related mortality in the United States because of both the high prevalence of advanced disease at diagnosis and the low rate of cure of early-stage disease. Thus, many

Full access

Biomarker-Based Treatment Selection in Non–Small Cell Lung Cancer

Wallace Akerley

“This is a very exciting time [in treating lung cancer]. We have always sought to use the right tool for the right job, with the focus placed on making better tools. We just kept varying the chemotherapy combinations leading to a plateau in

Full access

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel

Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian, Jun Lu, Xue-Yan Zhang, Hui-Min Wang, Bo Yan, Bo Zhang, Shu-Yuan Wang, Fang Hu, Chang-Hui Li, Hua Zhong, and Bao-Hui Han

Background For treatment of advanced non–small cell lung cancer (NSCLC) without driver mutations or high PD-L1 expression, chemotherapy remains the standard of care. However, the clinical benefit of chemotherapy is limited, with the objective